Papers And Originals

Clinical and Metabolic Study in Diabetic Patients Treated with Glibenclamide

Br Med J 1970; 2 doi: https://doi.org/10.1136/bmj.2.5709.568 (Published 06 June 1970) Cite this as: Br Med J 1970;2:568
  1. J. Anderson,
  2. R. Coulson,
  3. B. D. M. Grassick,
  4. B. A. Morris,
  5. W. D. Thomas,
  6. R. W. S. Tomlinson,
  7. F. Woodroffe

    Abstract

    A clinical and metabolic study of 32 patients treated with glibenclamide for a period of about one year confirmed that the drug is a potent stimulator of insulin release in maturity onset diabetes, and glibenclamide continued to have this action after a period of eight months. The drug is effective in doses as low as 2·5 mg., and the maximum effective dose is about 15 mg. No significant side-effects were found during the period of the study, in particular there was no alcohol flushing. The metabolic investigations have shown that the drug has some actions which are as yet unexplained.